Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Imatinib Mesylate 18Dasatinib 12Cyclophosphamide 11fludarabine phosphate 9nilotinib 8fludarabine 7Sirolimus 6ruxolitinib 5Tacrolimus 5Mycophenolic Acid 5Cytarabine 5Azacitidine 5Whole-Body Irradiation 4Ipilimumab 4Busulfan 4Bortezomib 4thymoglobulin 3bosutinib 3belinostat 3aldesleukin 3Specimen Handling 3Nivolumab 3Interleukin-2 3Granulocyte Colony-Stimulating Factor 3Clofarabine 3CTLA-4 Antigen 3Antilymphocyte Serum 3AP 1903 reagent 3zileuton 2tozasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Calcineurin Inhibitors × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡